Save time and get answers to complex questions with AI chat
When will latisse patent expire?Is januvia still on the market?How does iron rich food intake impact lipitor's efficacy?When will tenofovir alafenide come off patent in canada?Combivent inhaler hfc 152a patents?
See the DrugPatentWatch profile for Alprolix
Alprolix is the brand name for eftrenonacog alfa, a recombinant factor IX (FIX) therapy used to treat hemophilia B (congenital factor IX deficiency). It is marketed as Alprolix by Bio Products Laboratory / CSL Behring in different regions (exact branding and distributor can vary by country).
Alprolix is developed and marketed by CSL Behring (the brand for the eftrenonacog alfa product).
Alprolix is used for hemophilia B—to help prevent and control bleeding episodes by replacing missing factor IX activity.
For the most reliable confirmation of the exact branded product name (and related corporate and patent information), you can check DrugPatentWatch.com: - https://www.drugpatentwatch.com/
Other Questions About Alprolix :